What Ongoing Monitoring for Ozempic-Related Gastroparesis Involves

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Specific Drug Risks

If you're experiencing persistent nausea, vomiting, or abdominal pain after taking Ozempic, you may be wondering what tests can confirm gastroparesis. Decades of pharmacovigilance have established how to evaluate delayed gastric emptying linked to GLP-1 receptor agonists. This page explains the evidence doctors look for and what follow-up monitoring typically involves.

Medical Evidence Linking Ozempic to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in some formulations, for weight loss. Clinical data and postmarketing reports have raised concerns about a potential link between Ozempic and gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction. This narrative examines the medical evidence for this association, the adequacy of product warnings, and legal considerations for affected patients in North Carolina, including the statute of limitations for filing claims. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. The condition can lead to malnutrition, dehydration, and severe complications like bezoar formation. In the context of Ozempic use, gastrointestinal adverse reactions are well-documented. In placebo-controlled trials, gastrointestinal adverse events occurred more frequently among patients receiving Ozempic than placebo: 32.7% with Ozempic 0.5 mg, 36.4% with Ozempic 1 mg, and 34.0% with Ozempic 2 mg, compared to 15.3% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and diarrhea occurred during dose escalation, and discontinuation rates due to gastrointestinal adverse reactions were higher with Ozempic (3.1% for 0.5 mg, 3.8% for 1 mg) versus placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (3.5% with 0.5 mg, 2.7% with 1 mg), gastroesophageal reflux disease (1.9% with 0.5 mg, 1.5% with 1 mg), and gastritis (0.8% with 0.5 mg, 0.4% with 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these data do not explicitly list gastroparesis, the spectrum of delayed gastric emptying symptoms overlaps with the reported adverse effects.

Mechanistic Pathways and Warning Adequacy

Mechanistic pathways linking Ozempic to gastroparesis involve GLP-1 receptor agonism, which slows gastric motility. GLP-1 receptors are expressed in the gastrointestinal tract and central nervous system, and their activation delays gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This pharmacodynamic effect is intended to reduce postprandial glucose excursions but can become pathological in susceptible individuals, leading to symptomatic gastroparesis. Postmarketing reports have highlighted rare cases of pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, attributed to residual gastric contents despite adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for clinically significant delayed gastric emptying. The available data are insufficient to inform recommendations for mitigating aspiration risk, including whether modifying preoperative fasting or temporarily discontinuing Ozempic could reduce retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Regarding the adequacy of warnings, the Ozempic prescribing information includes gastrointestinal adverse reactions in the label but does not specifically mention gastroparesis as a distinct adverse event. The label notes that gastrointestinal adverse reactions occurred more frequently with Ozempic than placebo and that discontinuation rates were higher (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of explicit language about gastroparesis may leave patients and healthcare providers unaware of the potential for this serious condition. The postmarketing warning about pulmonary aspiration indirectly acknowledges delayed gastric emptying but does not directly address gastroparesis diagnosis or management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This gap in labeling could be relevant in legal claims alleging failure to warn.

Statute of Limitations for Ozempic Claims in North Carolina

For patients in North Carolina who have developed gastroparesis after using Ozempic, attorney-related considerations include the statute of limitations for product liability claims. In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered, through reasonable diligence. For claims involving defective drugs, the timeline may be complex because gastroparesis can develop insidiously over months or years of Ozempic use. The clock typically starts when the patient knew or should have known that the injury was caused by the drug. Given that Ozempic is often prescribed for chronic conditions, patients may not immediately associate their gastrointestinal symptoms with the medication. Legal counsel can help determine the applicable deadline based on individual circumstances, such as the date of diagnosis and the timeline between exposure and documented harm. The statute of limitations for wrongful death claims in North Carolina is two years from the date of death. The timeline between exposure to Ozempic and documented harm is critical for both medical and legal assessments. In clinical trials, gastrointestinal adverse reactions were most common during dose escalation, suggesting that symptoms can emerge early in treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, gastroparesis may develop after prolonged use, and the condition can persist even after drug discontinuation. Patients should document the start date of Ozempic use, the onset of symptoms, and any medical evaluations confirming delayed gastric emptying. This documentation is essential for establishing causation and meeting the statute of limitations.

Summary and Next Steps

In summary, the evidence indicates that Ozempic is associated with gastrointestinal adverse reactions that include symptoms consistent with gastroparesis, though the label does not explicitly warn of this condition. The mechanistic link through GLP-1 receptor agonism supports biological plausibility. Patients in North Carolina who have developed gastroparesis after using Ozempic should consult an attorney promptly to assess their legal options, given the three-year statute of limitations for personal injury claims. Medical records detailing the diagnosis and timeline of exposure are crucial for any potential litigation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For wrongful death claims, it is two years from the date of death. Because gastroparesis can develop gradually, the clock may start when the patient knew or should have known that Ozempic caused the condition. Consulting an attorney promptly is recommended.

Does Ozempic's label warn about gastroparesis?

The Ozempic prescribing information includes gastrointestinal adverse reactions but does not specifically mention gastroparesis as a distinct adverse event. The label notes that gastrointestinal adverse reactions occurred more frequently with Ozempic than placebo and that discontinuation rates were higher (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Postmarketing warnings about pulmonary aspiration indirectly acknowledge delayed gastric emptying but do not directly address gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.